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Objective To assess whether the risk of vulvodynia is associated
with previous use of oral contraceptives (OCs).
Design Longitudinal population-based study.
Setting Four counties in south-east Michigan, USA.
Population A population-based sample of women, aged 18
years and older, enrolled using random-digit dialling.
Methods Enrolled women completed surveys that included
information on demographic characteristics, health status,
current symptoms, past and present OC use, and a validated
screen for vulvodynia. The temporal relationship between OC use
and subsequent symptoms of vulvodynia was assessed using Cox
regression, with OC exposure modelled as a time-varying
covariate.
Main outcome measure Vulvodynia, as determined by
validated screen.
Results Women aged <50 years who provided data on OC use,
completed all questions required for the vulvodynia screen, and
had first sexual intercourse prior to the onset of vulvodynia
symptoms were eligible (n = 906). Of these, 71.2% (n = 645) had
used OCs. The vulvodynia screen was positive in 8.2% (n = 74)
for current vulvodynia and in 20.8% (n = 188) for past
vulvodynia. Although crude cross-tabulation suggested that
women with current or past vulvodynia were less likely to have
been exposed to OCs prior to the onset of pain (60.7%),
compared with those without this disorder (69.3%), the Cox
regression analysis identified no association between vulvodynia
and previous OC use (HR 1.08, 95% CI 0.81–1.43, P = 0.60).
This null finding persisted after controlling for ethnicity, marital
status, educational level, duration of use, and age at first OC use.
Conclusion For women aged <50 years of age, OC use did not
increase the risk of subsequent vulvodynia.
Keywords Chronic pain, oral contraceptives, population-based,
risk factors, vulvodynia.
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Introduction
Although vulvodynia is now known to be common,1–4 and
occurs at any age,1,5 little is known about risk factors for
this disorder. Oral contraceptives are commonly used by
women for reliable contraception as well as for urogenital
and menstrual symptom management. Yet, controversy
continues regarding the possible role of oral contraceptive
(OC) use in the risk for vulvodynia, with some studies sug-
gesting an increased risk in general,6 or related to age of
first use,6–8 duration,9 or strength of hormonal composi-
tion,6 whereas other studies report no association between
OC use and vulvodynia.10–12 These studies impact provider
recommendations to patients regarding the benefits versus
risks of starting or continuing the use of oral contracep-
tives, and hence sound data on this topic is crucial. How-
ever, past studies have been limited by patient selection
from clinical populations, and by the lack of adequate data
to establish whether OC use actually preceded the onset of
pain.10–12
We assessed the relationship between current or past
vulvodynia (based on validated screening criteria),13 and
the history and timing of OC use among a popula-
tion-based sample of women participants in the Woman to




Woman Health Study in south-east Michigan. These data
allowed the assessment of vulvodynia risk associated with
prior OC use using a survival analysis that included OC
use as a time-varying covariate, incorporating information
on the age of first intercourse, age of first OC exposure,
and duration of OC exposure.
Methods
This study was approved by the University of Michigan
Medical Institutional Review Board on 17 January 2008
(HUM00017098). Between September 2008 and November
2009, a population-based sample of 2542 women, aged
18 years and over, were recruited from a four-county area
in south-east Michigan, and were enrolled in the Woman
to Woman Health Study. Details of the sample were
reported previously.1 In brief, recruitment was conducted
using random-digit dialling. A woman aged 18 years or
older was randomly selected from each household con-
tacted, and was invited to participate in this study on
women’s health. Participants completed a brief telephone
interview, followed by an online or written 26–page survey,
which assessed demographic characteristics, contraceptive
and medical history, and current and past gynaecological
symptoms. Dates of initial vulvar pain, of onset and final
use of OCs, of reason for initial use, and for discontinua-
tion of OCs, and estimated duration of use were assessed.
Consent was implied by survey completion after reading
the cover letter detailing human subjects issues. Previously
validated survey-based criteria for predicting vulvodynia
case status were used to identify current cases, past cases,
and non-cases (control women).13 This validation study
had indicated that predicting the case status based on
symptoms and duration has very good consistency, com-
pared with that based on a clinical examination. Based on
these criteria, cases were defined as those with pain at the
opening to the vagina (either provokable or non-provokable/
spontaneous) that had been present for 3 months or
longer. Past cases met the same criteria, but reported that
the pain had resolved. Non-cases were women denying a
history of vulvar pain that had lasted 3 months or longer.
For this report, participants included only those aged
<50 years, a criterion adopted to minimise both recall bias
and the likelihood of exposure to postmenopausal hormone
therapy. We further limited analysis to those who provided
all data needed to assess vulvodynia case status, and who
provided information on OC use or non-use. We excluded
women who reported vulvodynia prior to the age of
15 years, on the premise that they were reporting symp-
toms reflective of childhood onset of vulvodynia, and prior
to the time they might be expected to take OCs. We also
excluded women whose age at first intercourse and symp-
toms of vulvodynia occurred in the same year, unless they
reported having had no pain at first intercourse, as we
could not otherwise determine whether or not the OC use
preceded the vulvodynia. Women who had never had inter-
course were excluded because intercourse is the activity
that will most consistently demonstrate the sensitivity to
women (and hence those not having intercourse may be
unaware of vulvar sensitivity).
Frequency distributions of each variable were calculated.
Non-parametric estimates of the distributions of OC start-
ing age and of vulvodynia onset were obtained by the
Kaplan–Meier method. Cross-tabulation between prior OC
use and subsequent vulvodynia status, and chi-square sta-
tistics, were calculated. A crude assessment of the relation-
ship between OC use and subsequent vulvodynia is
misleading, as it does not adequately control for the num-
ber of years a woman was at risk for starting OCs and for
presenting with vulvodynia (duration from first intercourse
to onset of vulvodynia or to current age). We used a Cox
regression model with age of onset of vulvodynia as the
outcome, and OC use modelled as a time-varying covari-
ate, allowing for a more accurate and comprehensive
assessment of risk. The participant was considered to be
taking OCs from the age at first use to the age of last
reported use. This analysis properly accounts for OC use
by allowing a subject to be in the exposed risk set for
developing vulvodynia only during the period that she was
an OC user. The age range ran from the age of first inter-
course to either the age at the onset of vulvodynia (event)
or the age at which the last survey was completed without
vulvodynia occurring (censoring). We also assessed the
model with 1 year added to the age of first intercourse to
minimise the possibility of incorrectly detecting an associa-
tion, because of the relationship between starting inter-
course and starting OCs. To allow for the possibility of
OC use affecting the risk of vulvodynia only after a sus-
tained duration of use, alternative definitions of the OC
time-dependent covariate set the variable as positive only
after 1, 2, 5, or 10 years had passed following first OC use.
As it was unknown whether past OC exposure might
impact future risk, we also tested a time-dependent covari-
ate that started OC exposure at the reported start year, but
continued OC exposure until the age at interview, regard-
less of stopping OC use.
We tested for a changing risk of OCs with increasing age
by including an age*OC interaction in the model. The
assessment of risk at various ages of first OC use was fur-
ther demonstrated using analyses of subsets of women who
started OCs at various ages, compared with those not using
OCs. Covariates added to all models included ethnicity,
education, and marital status. Statistical analyses were car-
ried out in PASW STATISTICS 18.0 (SPSS, Chicago, IL, USA)
and SAS 9.3 (SAS/STAT 9.3 User’s Guide; SAS Institute, Cary,
NC, USA).
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Results
Of the 1083 women aged 18–49 years in the Woman to
Woman Health Study who completed the initial survey, 1076
(99.4%) completed the question on their use of OCs. Of
these, 1032 (95.9%) completed the questions needed to pre-
dict the presence of vulvodynia. We excluded 17 women who
reported symptoms of vulvodynia prior to the age of
15 years, 44 women who reported identical ages at first inter-
course and the onset of vulvodynia symptoms, and who had
not had pain-free intercourse preceding the onset of vulvo-
dynia symptoms, 18 women who reported vulvodynia symp-
toms that started prior to first intercourse, 37 women who
had not had intercourse, and 10 women who did not give an
age of first intercourse. Thus, a total of 906 of the 1083
women (83.7%) were eligible for this analysis.
The 906 women included in the analysis had a mean age
of 36.9  8.6 years: 71.8% were white, 18.5% were black,
and 3.9% were Hispanic; 55.0% had completed college;
69.7% were married or cohabiting; 56.9% had a household
income ≥$60 000; and 44.9% found it difficult to pay for
basics (food, shelter, heat, and health care). Compared with
the 177 women (of the original 1083) who were ineligible for
this analysis, no differences were found in ethnicity or educa-
tional level; however, compared with those who were
ineligible, eligible women were more likely to be older
(mean = 36.9 versus 32.4 years old, P < 0.001), have a
household income of ≥$60 000 (56.9 versus 43.4%,
P = 0.002), be married (69.7 versus 41.0%, P < 0.001), and
have ever taken OCs (71.2 versus 50.6%, P < 0.001). These
differences are in part an artifact of the inclusion criterion
that required the women to have had intercourse at some
time: a characteristic associated in our data with older age,
being married, being a college graduate, being white, and
having ever taken OCs. When only those women who had
ever had intercourse were compared with those in the
included and excluded groups, the only statistically signifi-
cant differences found were the greater likelihood among
those included of being married (69.7 versus 58.9%,
P = 0.005), and of having a household income of ≥$60 000
(56.9 versus 43.8%, P = 0.01).
Vulvodynia screening of the 906 women identified 74
women positive for vulvodynia (with a prevalence of 8.2%,
95% CI 6.4–10.0%), and an additional 188 women
screened positive for past vulvodynia (20.8%, 95% CI 18.2–
23.4%). The age of the reported onset of vulvar pain ran-
ged from 15 (lower limit eligible for this analysis) to
48 years of age (median 25.0 years, 95% CI 23.4–26.6;
Figure 1A, Kaplan–Meier estimate). The estimated duration
of pain from onset to resolution ranged from less than a
year to 29 years (Figure 1B). Only 1 of the 74 (1.4%)
women screening positive for vulvodynia, and 5 of the 188
(2.7%) with past vulvodynia, reported having been given a
diagnosis of vulvodynia previously, decreasing the likeli-
hood of bias related to previously suggested risk factors.
Women with current or past vulvodynia, when compared
with controls, were similar in age (36.8  8.2 versus
37.0  8.8 years, P = 0.71), high school graduation rates
(97.3 versus 97.2%, P = 0.43), ethnicity (75.2 versus 70.5%
white, P = 0.15), being married or cohabiting (70.8 versus
69.3%, P = 0.66), and ability to pay for basics (42.0 versus
45.7%, P = 0.44).
Oral contraceptive use at some point in their lifetime was
reported by 71.2% (n = 645) of the participants, with first
use of OCs occurring at 12–39 years of age (Figure 2A), with
a median age of first use of 19.0 years. Current OC use was
reported by 15.0% (n = 136). The duration of use (estimated
from ages of first and last use, and censored at the time of
the survey for current users) ranged from less than a year to
A
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Figure 1. (A) Age of vulvodynia onset (Kaplan–Meier estimation); (B)
duration of vulvodynia, among those who have current or past
vulvodynia.
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35 years (Figure 2B), with a median duration of use of
10.0 years. The number of brands used and the reasons for
starting and stopping OCs are shown in Table 1. Women
who met criteria for case and/or past case status did not dif-
fer from the non-cases in whether they were currently taking
OCs, age at first use of OCs, number of brands used, dura-
tion of use, or years since last use of OCs. Reasons for initiat-
ing and discontinuing OC use were similar also. Comparable
results were obtained when assessing the characteristics of
those with current vulvodynia only, compared with
non-cases (data not shown).
The timing of OC use compared with the onset of vulvo-
dynia was also assessed (Figure 3). Women considered
‘exposed’ to OCs (n = 605, 66.8%) were those who started
using OCs who had never previously developed symptoms
of vulvodynia. Those who had either not taken OCs to date
(n = 261, 28.8%) or started taking OCs at or after the age
of onset of vulvar pain, consistent with vulvodynia
(n = 40, 4.4%), were considered unexposed.
The demographic characteristics of women who were
categorised as exposed and unexposed to OCs were
assessed. Compared with those not exposed, women who
had been exposed to OCs were more likely to be older
(37.9  8.2 versus 35.0  9.1 years, P < 0.0001), be white
(78.6% [473] versus 58.1% [175], P < 0.0001), have started
intercourse at a younger age (17.4  3.0 versus 18.0
 3.9 years, P = 0.02), be married (74.5% [448] versus
60.3% [179], P < 0.0001), and have a higher income
A
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Figure 2. (A) Ages at which OCs were first started among those who
have used OCs; (B) duration of OC use among those who took or are
taking OCs.
Figure 3. Categories comprising the exposed and non-exposed
subgroups, stratified by case or control status.
Table 1. Characteristics of oral contraceptive use (multiple options
could be selected)
Oral contraceptive use Prevalence
Number of different brands used
Mean 2.6  1.5, range 1–12, median 2
Reason for initial use (top five reasons only)*
1 to prevent pregnancy 510 (79.9%)
2 to regulate periods 170 (26.2%)
3 to decrease dysmenorrhea 149 (23.4%)
4 to decrease heavy menstrual bleeding 102 (16.0%)
5 to decrease premenstrual symptoms 76 (11.9%)
Reason for discontinuation if no longer using (top five
reasons only)**
1 no longer needed 192 (38.6%)
2 concerned about possible risks 108 (21.7%)
3 had side effects 109 (21.9%)
4 desired other type of contraception 48 (9.7%)
5 too expensive 36 (7.2%)
*Other reasons included to treat acne (6.4%), or because her
parents (8.6%), her partner (5.5%), or her physician (16.0%)
recommended them.
**Other reasons included no partner (6.2%), had a hysterectomy
(2.4%), reached menopause (1.6%), or doctor recommended
discontinuation (6.8%).
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(65.0% [346] versus 40.5% [106] with a household income
of ≥$60 000, P < 0.0001).
Among those with current or past vulvodynia (n = 262),
only 60.7% (n = 159) reported the use of OCs anytime
prior to the onset of the symptoms, compared with 69.3%
(n = 446) of those who screened negative for current or
past vulvodynia (P = 0.013, RR 0.69, 95% CI 0.51–0.92),
suggesting a protective role of OC use. As described in the
Methods, this crude analysis gives misleading results
because of the variable number of years each participant
was at risk for taking OCs and for presenting with symp-
toms of vulvodynia, and the variable number of years she
took OCs. Hence, Cox regression on the age of onset of
vulvodynia, with time-dependent OC covariates, was used
to assess the hazard ratio for OC use. The hazard ratio for
time-dependent OC use (versus non-use) was 1.08 (95% CI
0.81–1.43), with a non-significant P = 0.60 (controlled for
ethnicity, marital status, and educational attainment;
Table 2). Hence, the rate of vulvodynia onset did not differ
significantly among those who had used OCs compared
with those who had not, when accounting for the the spe-
cific years each woman took OCs. We further assessed
whether having ever used OCs altered the risk of develop-
ing vulvodynia, i.e. by modelling risk if OCs were started,
but not considering the time of discontinuation. No
increased risk for vulvodynia if the woman had ever taken
OCs was noted (Table 2). When the start time of OC use
was shifted by 1, 2, 5, or 10 years (testing whether a dura-
tion of 1, 2, 5, or 10 years might impact risk, when undif-
ferentiated current use did not), no significant OC effect
was found (Table 2). Furthermore, testing for a change in
OC risk for subsequent vulvodynia by age at first use did
not reveal a significant effect (Table 2). To further show
this lack of an OC effect across four age (of first use)
groups, a separate model for each age group was run (OCs
started at ≤16, 17–18, 19–20, and >20 years of age), each
selecting participants who started OCs in the given age
interval, compared with those never exposed to OCs. This
analysis indicated no association between age at first use




In this population-based sample of women, we found no
increased risk of vulvodynia following OC use. The evalua-
tion of subgroups that might demonstrate an increased
risk, including those with a younger age at first OC use, or
those with a longer duration of OC use, indicated that the
risk of developing vulvodynia was not increased by OC use
in any of these specific subgroups, although we did observe
a non-significant trend towards a decreased risk with
longer durations of OC use. These data provide evidence
against the clinical belief that OC use is associated with risk
of vulvodynia.
The evidence for and against an association between OC
use and vulvodynia has been controversial. Some studies
were limited by study-design issues, including failure to
assess whether OC use preceded the vulvar pain, with most
studies targeting a clinic-based population that may not be
representative of the community at large. Two studies tar-
geting women seen in vulvar specialty clinics,6,7 and one
using a combination of a population-based cohort as well
as a clinic-based cohort,8 found younger age at OC onset
was associated with increased risk. It is possible that these
results may reflect a longer time between initial exposure
and years observed (to their present age) in which they
may develop vulvodynia. We did not find an increased risk
among those starting OCs at a younger age. Other pub-
lished reports suggesting a relationship between duration
of OC use and vulvodynia in young women have had
small samples and minimal information about OC use,
thereby limiting the quality of their evidence.9,14 Other
studies that have similarly shown no association or a
decreased risk of vulvodynia with OC use did not assess
the timing of OC use compared with the onset of vulvar
pain, thereby limiting their findings,10–12,15,16 or had a
small sample size.2
Table 2. Hazard ratios for the development of vulvodynia following




Hazard ratio based on time-dependent
OC use between the ages of start and
stop of OCs
1.08 (0.81–1.43) 0.60
Hazard ratio based on time-dependent
continuous OC use from age of
starting OCs
1.02 (0.77–1.36) 0.89
Hazards for various minimal durations of OC use, assuming a
latency period**
Minimum 1–year OC use (OC age + 1) 1.00 (0.75–1.32) 0.97
Minimum 2–year OC use (OC age + 2) 0.98 (0.73–1.32) 0.89
Minimum 5–year OC use (OC age + 5) 1.08 (0.77–1.52) 0.65
Minimum 10–year OC use (OC age + 10) 0.68 (0.41–1.15) 0.15
Hazard ratio of the interaction term:
age*OC use
0.97 (0.94–1.02) 0.29
Using the duration from age of OC onset to discontinuation or age
at survey completion (or other interval, as noted) to create the
time-dependent covariate(s), with age at first intercourse and age at
vulvodynia onset as the events. Controlled for marital status,
education, and ethnicity (age is already the time axis of the model,
and is therefore fully adjusted).
**In each case, the time-dependent OC use variable returned to
zero at the cessation of OC use.
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In a case–control study of 138 women with secondary ves-
tibulodynia and 309 controls (with a mean age of 22 years),6
Bouchard and colleagues additionally reported an increased
risk of vulvodynia among those using ‘high-risk’ oral contra-
ceptives, which they defined as high progestational, high
androgenic, and low estrogenic compounds; however,
because of the low numbers of women who had taken only
high-risk OCs (<2% of participants), the confidence limit
was quite wide. In the current study, women across the
reproductive age range were included, and hence we reported
on a longer period of time in which they may have taken
OCs. The validity of reporting accurate brands and durations
of individual oral contraceptives over that time frame is lim-
ited, and hence no stratification on hormonal content was
attempted. We anticipate the proportion of women who had
only taken high-risk oral contraceptives, as defined by Bou-
chard et al.,6 would be similarly small, and hence would not
have altered the findings.
The data on OC use and genital pain in general are simi-
larly inconsistent, with some studies reporting increased dys-
menorrhea with OCs, but most studies reporting less.17 The
clinical data on dyspareunia after OC use is also conflicting.
Caruso noted decreased sexual activity and desire among
young women starting 15 lg ethinyl estradiol OCs, but no
significant change in reported dyspareunia,18 but later sug-
gested a lessening of dyspareunia following 3 and 6 months
of Yasminelle and Yaz use.19
Strengths and limitations
This study has several strengths, including the use of a
validated screening instrument to predict the vulvodynia
diagnosis,13 random population-based recruitment, and con-
sideration of the timing of starting OC use compared with
the onset of vulvodynia pain. We limited our analysis to
those who were of an age in which exposure might occur
(≥15 years) and who had had intercourse prior to the onset
of symptoms of vulvodynia. Notably, when we repeated the
Cox analysis without these age and intercourse restrictions,
the results were similar (data not presented). However, limi-
tations also exist. Despite the excellent validity of screening
for vulvodynia on surveys,13,20 some of the women predicted
to have vulvodynia may have other dermatological or infec-
tious diagnoses; previous studies suggest that this proportion
would be small. Similarly, residual confounding may remain
if other factors impact OC use (side effects, need for contra-
ception, or the use of other contraceptive modalities). In
addition, women may start and stop OCs several times over
their reproductive years, and may take a number of OC for-
mulations during that time, including those containing only
progestogens (seen in 2.2% of current users in this popula-
tion). This study did not have the data to assess the potential
impact of these variations.
Conclusion
The use of OCs was not found to increase the risk of
new-onset vulvodynia in this population-based sample of
women aged <50 years, and trends suggested that a longer
duration of OC use might decrease the risk of developing
vulvodynia. Further work is needed to assess these findings
in a prospective study, including subgroups that may differ
in risk, and to assess the impact of potential OC use on
the characteristics and duration of vulvodynia.
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